Biopartners Receives European Union Marketing Authorisation for its Biosimilar Recombinant Human Growth Hormone - Valtropin®
Biopartners has received marketing authorisation for the European Union from the European Commission for its biosimilar medicinal product Valtropin, a recombinant human growth hormone used for the treatment of human growth deficiency in children and Turner's Syndrome. Biopartners, jointly with LG Life Sciences, has co-developed a number of biopharmaceutical products including Valtropin and a sustained release formulation of Valtropin. Biopartners in-licensed Valtropin from LG Life Sciences and has commercialization rights for Valtropin in Europe, Japan and other parts of Asia.
"We are delighted to have gained EU marketing authorisation for Valtropin" stated Mr Jean-Noël Treilles, CEO of Biopartners. "As the first product in our broad and advanced pipeline to gain authorisation, this marks a major milestone for Biopartners. We aim to make Valtropin available to healthcare professionals and patients through our distributors before the end of the year. Biopartners is currently developing a sustained release version of Valtropin that is currently in Phase III clinical trials."
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.